Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard E Greenberg

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|December 19, 2003
The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteersWalter K Kraft, Barry Steiger, Don Beussink, et al.
Therapeutic Innovation & Regulatory Science|November 25, 2014
Investigators' Experience With Expedited Safety Reports Prior to the FDA's Final IND Safety Reporting RuleJudith M Kramer, David Vock, Howard E Greenberg, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacinJules I Schwartz, Bret J Musser, Wesley K Tanaka, et al.
Journal of Clinical Pharmacology|September 16, 2003
Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregationJoanne Burke, Walter K Kraft, Howard E Greenberg, et al.
Journal of Clinical Pharmacology|September 5, 2003
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceMaria L Veronese, Lisa P Gillen, Joanne P Burke, et al.
Drug Metabolism and Drug Interactions|October 12, 2013
Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotypingWei Tai, Sheryl L Gong, Shirley M Tsunoda, et al.
Clinical and Vaccine Immunology : CVI|October 15, 2010
Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humansClayton Harro, Robert Betts, Walter Orenstein, et al.
Journal of Clinical Pharmacology|February 20, 2004
Indinavir and rifabutin drug interactions in healthy volunteersWalter K Kraft, Jacqueline B McCrea, Gregory A Winchell, et al.
Journal of Clinical Pharmacology|May 4, 2019
Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy AdultsJincheng Yang, Mina Nikanjam, Edmund V Capparelli, et al.
Journal of Clinical Pharmacology|April 18, 2018
Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic ApproachJincheng Yang, Maulik Patel, Mina Nikanjam, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|December 19, 2003
The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteersWalter K Kraft, Barry Steiger, Don Beussink, et al.
Therapeutic Innovation & Regulatory Science|November 25, 2014
Investigators' Experience With Expedited Safety Reports Prior to the FDA's Final IND Safety Reporting RuleJudith M Kramer, David Vock, Howard E Greenberg, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacinJules I Schwartz, Bret J Musser, Wesley K Tanaka, et al.
Journal of Clinical Pharmacology|September 16, 2003
Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregationJoanne Burke, Walter K Kraft, Howard E Greenberg, et al.
Journal of Clinical Pharmacology|September 5, 2003
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceMaria L Veronese, Lisa P Gillen, Joanne P Burke, et al.
Drug Metabolism and Drug Interactions|October 12, 2013
Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotypingWei Tai, Sheryl L Gong, Shirley M Tsunoda, et al.
Clinical and Vaccine Immunology : CVI|October 15, 2010
Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humansClayton Harro, Robert Betts, Walter Orenstein, et al.
Journal of Clinical Pharmacology|February 20, 2004
Indinavir and rifabutin drug interactions in healthy volunteersWalter K Kraft, Jacqueline B McCrea, Gregory A Winchell, et al.
Journal of Clinical Pharmacology|May 4, 2019
Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy AdultsJincheng Yang, Mina Nikanjam, Edmund V Capparelli, et al.
Journal of Clinical Pharmacology|April 18, 2018
Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic ApproachJincheng Yang, Maulik Patel, Mina Nikanjam, et al.
Pageof 3